

- tion: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. *Lancet Infect. Dis.* 12:671–677. [http://dx.doi.org/10.1016/S1473-3099\(12\)70138-X](http://dx.doi.org/10.1016/S1473-3099(12)70138-X).
20. Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K. 2011. Rapid emergence of telaprevir resistant hepatitis C virus strain from wild-type clone in vivo. *Hepatology* 54:781–788. <http://dx.doi.org/10.1002/hep.24460>.
  21. Lauck M, Alvarado-Mora MV, Becker EA, Bhattacharya D, Striker R, Hughes AL, Carrilho FJ, O'Connor DH, Pinho JR. 2012. Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing. *J. Virol.* 86:3952–3960. <http://dx.doi.org/10.1128/JVI.06627-11>.
  22. Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, Chiba T. 2011. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. *PLoS One* 6:e24907. <http://dx.doi.org/10.1371/journal.pone.0024907>.
  23. Ninomiya M, Ueno Y, Funayama R, Nagashima T, Nishida Y, Kondo Y, Inoue J, Kakazu E, Kimura O, Nakayama K, Shimosegawa T. 2012. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. *J. Clin. Microbiol.* 50:857–866. <http://dx.doi.org/10.1128/JCM.05715-11>.
  24. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arihiro K, Kubo M, Nakamura Y, Chayama K. 2010. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. *J. Hepatol.* 53:439–443. <http://dx.doi.org/10.1016/j.jhep.2010.03.022>.
  25. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* 10:R25. <http://dx.doi.org/10.1186/gb-2009-10-3-r25>.
  26. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2013. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. *J. Med. Virol.* 85:1028–1036. <http://dx.doi.org/10.1002/jmv.23579>.
  27. Lavanchy D. 2009. The global burden of hepatitis C. *Liver Int.* 29(Suppl 1):74–81. <http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x>.
  28. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology* 55:742–748. <http://dx.doi.org/10.1002/hep.24724>.
  29. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. 2013. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. *J. Hepatol.* 58:646–654. <http://dx.doi.org/10.1016/j.jhep.2012.11.012>.
  30. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. 2013. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. *J. Hepatol.* 58:655–662. <http://dx.doi.org/10.1016/j.jhep.2012.09.037>.
  31. Cubero M, Esteban JJ, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J. 2008. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. *Virology* 370:237–245. <http://dx.doi.org/10.1016/j.virol.2007.10.006>.
  32. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. *Hepatology* 48:1769–1778. <http://dx.doi.org/10.1002/hep.22549>.
  33. Lu L, Mo H, Pilot-Matias TJ, Molla A. 2007. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. *Antimicrob. Agents Chemother.* 51:1889–1896. <http://dx.doi.org/10.1128/AAC.01004-06>.
  34. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H. 2012. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. *J. Clin. Virol.* 54:352–354. <http://dx.doi.org/10.1016/j.jcv.2012.04.024>.
  35. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. *Antimicrob. Agents Chemother.* 54:3641–3650. <http://dx.doi.org/10.1128/AAC.00556-10>.

